Array
(
[Ovarian Cancer] => Array
(
[Austin] => https://www.survivornet.com/austin/
[Baltimore] => https://www.survivornet.com/baltimore/
[Charlotte] => https://www.survivornet.com/charlotte/
[Cleveland] => https://www.survivornet.com/cleveland/
[Columbus] => https://www.survivornet.com/columbus/
[Dallas / Ft. Worth] => https://www.survivornet.com/dallas-ftworth/
[Denver] => https://www.survivornet.com/denver/
[Detroit] => https://www.survivornet.com/detroit/
[Indianapolis] => https://www.survivornet.com/indianapolis-ovarian-cancer/
[Louisville] => https://www.survivornet.com/louisville/
[Memphis] => https://www.survivornet.com/memphis/
[Minneapolis] => https://www.survivornet.com/minneapolis/
[Nashville] => https://www.survivornet.com/nashville/
[Phoenix] => https://www.survivornet.com/phoenix/
[Portland] => https://www.survivornet.com/portland/
[Salt Lake City] => https://www.survivornet.com/salt-lake-city/
[San Antonio] => https://www.survivornet.com/san-antonio/
[San Diego] => https://www.survivornet.com/san-diego/
[San Francisco] => https://www.survivornet.com/san-francisco/
[San Jose] => https://www.survivornet.com/san-jose/
[Seattle] => https://www.survivornet.com/seattle/
) [Multiple Myeloma] => Array
(
[Ann Arbor] => https://www.survivornet.com/ann-arbor-michigan-multiple-myeloma-treatment/
[Miami] => https://www.survivornet.com/miami-florida-multiple-myeloma-treatment/
[Phoenix] => https://www.survivornet.com/phoenix-arizona-multiple-myeloma-treatment/
) [Glioma] => Array
(
[Midwest] => https://www.survivornet.com/midwest/
[Mountain States] => https://www.survivornet.com/glioma-mountain-states/
[Southeast] => https://www.survivornet.com/southeast/
) )
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations Summary The purpose of this study is to assess the patient's preference for nivolumab subcutaneous (SC) or nivolumab + relatlimab fixed-dose combination (FDC) SC and provide patient experience data by route of administration. This study will also generate safety data which will further characterize the safety profile of patients switching the route of administration from intravenous (IV) to SC.
View Eligibility Criteria Eligibility Criteria Inclusion Criteria:melanoma and have not had previous treatment for their cancer, or resected melanoma and have had the cancer removed fully with surgery no later than 12 weeks before the start of treatment and confirmed free of diseaseradiation , any cancer in the eyes or mucous membranes (cells that cover inside surface of parts of the body and keep it moist), any autoimmune disease, or any condition that is being treated with steroids for inflammation (corticosteroids) or medication to decrease the body's immune system response (immunosuppressive drugs)
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 35 Locations for this study
Alaska Oncology & Hematology, LLC Anchorage Alaska, 99508, United States
More Info
Mayo Clinic Hospital - Phoenix Phoenix Arizona, 85054, United States
More Info
University of California, San Francisco, Medical Center at Mount Zion San Francisco California, 94115, United States
More Info
Local Institution - 0034 Atlanta Georgia, 30342, United States
More Info
Saint Elizabeth Healthcare Edgewood Kentucky, 41017, United States
More Info
University of New Mexico Cancer Center Albuquerque New Mexico, 87106, United States
More Info
Icahn School of Medicine at Mount Sinai (ISMMS) - The Derald H. Ruttenberg Treatment Center
Swedish Cancer Institute Seattle Washington, 98104, United States
More Info
Local Institution - 0024
Local Institution - 0002
Local Institution - 0001
Local Institution - 0015 Las Condes Santiago, 83310, Chile
More Info
Servicios Medicos e Investigacion Biocenter SpA Concepcion , 40701, Chile
More Info
Local Institution - 0016 Las Condes , 75500, Chile
More Info
Bioclinic of Thessaloniki Thessaloniki B, 546 2, Greece
More Info
Local Institution - 0014 Athens I, 115 2, Greece
More Info
Local Institution - 0031
Athens Medical Center Marousi I, 151 2, Greece
More Info
Metropolitan General Hospital Holargos, Athens , 155 6, Greece
More Info
Metropolitan Hospital, Department of Oncology Peiraias , 185 4, Greece
More Info
Local Institution - 0033 Thessaloniki , 564 2, Greece
More Info
ASST Papa Giovanni XXIII Bergamo BG, 24127, Italy
More Info
Local Institution - 0035 Meldola FC, 47014, Italy
More Info
Istituto Europeo di Oncologia Milan MI, 20141, Italy
More Info
Local Institution - 0012 Padova PD, 35128, Italy
More Info
Istituto Nazionale Tumori Regina Elena Roma RM, 00144, Italy
More Info
Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino Torino TO, 10126, Italy
More Info
Local Institution - 0026 Napoli , 80131, Italy
More Info
Hospital de la Santa Creu i Sant Pau Barcelona B, 08025, Spain
More Info
Local Institution - 0022 Barcelona B, 08908, Spain
More Info
Hospital Universitario Virgen Arrixaca Cartagena MU, 30120, Spain
More Info
Local Institution - 0020 Badalona , 08916, Spain
More Info
Local Institution - 0027 Cantabria , 39008, Spain
More Info
Hospital San Pedro de Alcántara San Pedro Alcántara, Málaga , 10002, Spain
More Info
Hospital Universitario Virgen del Rocío Sevilla , 41013, Spain
More Info How clear is this clinincal trial information?
Sign Up Sign up now for access to powerful tools, top experts, and customized information to help you fight cancer.
Personalized content tailored to your profile and disease type Access exclusive patient guides Breaking treatment information and expert perspectives and more... Sign Up Now Already have an account? Sign In
Sign Up Already have an account? Sign In
Sign In Don't have an account? Sign Up
Password reset is unavailable because your account was created using 'Sign Up with Google. To continue, please use the Google sign-in button below. Don't have an account? Sign Up
